Navigation Links
Microfluidics International Corporation Announces Second Quarter 2009 Financial Results
Date:8/11/2009

other words and terms of similar meaning. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Among the factors that could cause actual results and outcomes to differ materially from those contained in such forward-looking statements are the following: our ability to access sufficient working capital, including a new working capital line; our continued compliance with the representations, warranties and covenants under our existing convertible debenture; our continued history of losses, which includes net losses in three of the last five fiscal years; the timing and size of customer orders for our products; the adoption, timing and performance of new technology and products developed by us; changes and advances in technology that may make our products obsolete or reduce demand for our products; our ability to protect and maintain the confidentiality of our intellectual property; our ability to retain key employees and our reliance on a new management team; changes in governmental rules and regulations, including those regulating the exportation of goods; and general economic and business conditions and the financial crisis, including those adversely effecting the pharmaceutical and biotechnology industries. For a more detailed discussion of risks and uncertainties which could cause actual results to differ from those contained in our forward-looking statements, see Item 1A, "Risk Factors" of our most recently filed Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 and our other periodic reports filed with the SEC. You should not place undue reliance on our forward-looking statements, which speak only as of the date they are made. We are providing this information as of this date, and we do not undertake to update the information included in this press release, whether as a result of new information, future events or o
'/>"/>
SOURCE Microfluidics International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. RainDance Technologies to Present Sequence Enrichment Using Droplet-Based Microfluidics Workshop at ASHG 2008
2. GEN Reports on Growing Reliance on Microfluidics Technology
3. Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries
4. Nanopoint Applies CE Mark to Its cellTRAY(R) Imaging and Microfluidics Systems
5. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
6. Microfluidics International Corporation to Report Second Quarter 2009 Financial Results on August 11, 2009
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
9. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
10. Arrow International Files and Mails Definitive Proxy Materials
11. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 Senomyx , Inc. ... taste science technologies to discover, develop, and commercialize novel ... , Ph.D., the Company,s Vice President, Biology and ... Relations & Corporate Communications, will present an overview of ... 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time) during ...
(Date:5/24/2013)... 2013 Many factors impact tissues targeting ... efflux transporters at the blood-tissue barrier. Even when tissue ... fractions in the tissue rather than the total tissue ... is required to guide lead optimization, predict in vivo ... variables that may impact the likely human clinical dose. ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") ... science-based research and development, sales and marketing of ... announced today that it is awarding exclusive Vestiage ... of Reluma Skin Illuminating Facial Care. Qualified applicants ... sending an email to info(at)vestiageinc(dot)com and putting RELUMA ...
(Date:5/23/2013)... , May 24, 2013 ... angefertigt – Bei der englischen ... , 91 % der Teilnehmer einer groß angelegten ... 20 % laut GINA [*] -Definition [1] als ... Menschen mit Asthma generell einer von vier Denkweisen zugeordnet ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7
... Inc. (Nasdaq: LXRX ) today announced that Arthur ... will present,at the BIO InvestorForum at The Palace Hotel ... 11:00 a.m. Pacific Time. A live webcast of ... http://www.lexpharma.com . An archived version of the,webcast will ...
... GENZ ) announced today that it has ... the treatment of Hunter syndrome.,Elaprase is an enzyme ... and Genzyme is commercializing the product in Japan ... Shire. Genzyme intends,to launch Elaprase this quarter, following ...
... COHR ) today announced that, as anticipated, on ... letter indicating that,the Company is not currently in compliance ... 4350(e) and 4350(g) due to,its failure to hold an ... 30, 2007. The notice stated that the failure could,serve ...
Cached Biology Technology:Lexicon Pharmaceuticals to Present at Bio InvestorForum 2Genzyme Receives Approval to Market Elaprase(R) in Japan 2Genzyme Receives Approval to Market Elaprase(R) in Japan 3Genzyme Receives Approval to Market Elaprase(R) in Japan 4Coherent, Inc. Receives Expected Letter from NASDAQ 2
(Date:5/24/2013)... the world,s largest and fastest growing open-access publishers, today ... in Physics . , A broad scope journal covering ... an open-science and interactive web platform for the research ... , Frontiers, real-time and interactive peer-review enables fast, ... types. With an average of three months from submission ...
(Date:5/24/2013)... the search for medication against Alzheimer,s disease, scientists have focused ... down Amyloid beta (A-beta). After all, it is the accumulation ... of Alzheimer,s patients. Starting point for the formation of A-beta ... the first to unravel the function of APPL the ... fruit flies. , Alessia Soldano (VIB/KU Leuven): "We have ...
(Date:5/23/2013)... 13,000 ships per year, carrying more than 284 million tons ... $1.8 billion dollars in toll fees for the Panama Canal ... million gallons of water are used from Gatun Lake, which ... people living in the isthmus. , However, the advent ... percent of the ships at sea, has demanded change. The ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3A new strategy required in the search for Alzheimer's drugs? 2Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3
... -- (Nov. 14, 2011) -- To protect Houston and ... experts recommends building a floodgate across the Houston Ship ... on Galveston Island and the developed west side of ... coastal recreation area to sustainably use wetlands that act ...
... 14, 2011Mary Ann Liebert, Inc., publishers ( http://www.liebertpub.com ... and Technology , a highly innovative, bimonthly peer-reviewed ... has the potential to significantly improve human health, ... and innovative results, essential data, cutting-edge discoveries, thorough ...
... Hull, Bristol and Frankfurt have shown that a new ... on small samples of biological proteins, particularly proteins that ... enhanced form of nuclear magnetic resonance (NMR) spectroscopy, could ... within hours, rather than weeks or months, radically speeding ...
Cached Biology News:Protecting Houston from the next big hurricane 2Protecting Houston from the next big hurricane 3New journal on disruptive science and technology launching in 2012 2New technique enables study of 'challenging' proteins 2
E2F2 protein...
Anti-DDDDK-Tag (Enterokinase Cleavage Site), Agarose Conjugate Research Focus: tag Storage: 4C Shipping Temperature: 4C...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Biology Products: